TY - JOUR
T1 - Stage I non-Hodgkin lymphoma
T2 - no plateau in disease-specific survival ?
AU - Chihara, Dai
AU - Oki, Yasuhiro
AU - Fanale, Michelle A.
AU - Westin, Jason R.
AU - Nastoupil, Loretta J.
AU - Neelapu, Sattva
AU - Fayad, Luis
AU - Fowler, Nathan H.
AU - Cheah, Chan Yoon
N1 - Funding Information:
Conflict of interest Dr Fanale reports grants and personal consulting fees through 06/04/18 from Seattle Genetics and salary and stocks from 10/01/18 following the start of her employment with Seattle Genetics. Grants and personal fees from Takeda through 06/04/18, grants and personal fees from Celgene through 06/04/18, grants from ADC Therapeutics through 06/04/18, grants and personal fees from BMS through 06/04/18, grants and personal fees from Merck through 06/04/ 18, grants from Molecular Templates through 06/04/18, personal fees from Bayer through 06/04/18, personal fees from Spectrum through 06/ 04/18, grants from MedImmune through 06/04/18, grants from Gilead through 06/04/18, and grants from Genentech through 06/04/18.
Publisher Copyright:
© 2019, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2019/5/1
Y1 - 2019/5/1
N2 - Stage I non-Hodgkin lymphoma (NHL) is rare; prognostic impact of different histologic subtypes and treatment modality is still unclear. We used the Surveillance, Epidemiology and End Results (SEER) database to evaluate survival outcomes among adult patients (age ≥ 18 years, N = 58,230) diagnosed with stage I NHL of various histologic subtypes between 1998 and 2014. Five-year disease-specific survival of patients with stage I diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), Burkitt lymphoma (BL), mantle cell lymphoma (MCL), and peripheral T cell lymphoma (PTCL) was 82%, 92%, 95%, 89%, 78%, 77%, and 77%, respectively. The median disease-specific survival was not reached in all histologic subtypes analyzed; however, there does not appear to be a plateau in disease-specific survival of patients with stage I NHL irrespective of subtypes. Although lymphoma was the most common cause of death (40.7%), death from other cancer (17.4%) and cardiovascular disease (13.6%) were also frequent. Chemotherapy appeared favorably associated with OS in patients with DLBCL, BL, and MCL while patients with FL, MZL, SLL, and PTCL who require chemotherapy for initial treatment showed shorter OS. Patients with stage I NHL have favorable disease-specific survival; however, no plateau was seen regardless of histologic subtypes thus suggesting that patients may need attention and follow-up even in aggressive lymphomas after 5 years of remission.
AB - Stage I non-Hodgkin lymphoma (NHL) is rare; prognostic impact of different histologic subtypes and treatment modality is still unclear. We used the Surveillance, Epidemiology and End Results (SEER) database to evaluate survival outcomes among adult patients (age ≥ 18 years, N = 58,230) diagnosed with stage I NHL of various histologic subtypes between 1998 and 2014. Five-year disease-specific survival of patients with stage I diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), Burkitt lymphoma (BL), mantle cell lymphoma (MCL), and peripheral T cell lymphoma (PTCL) was 82%, 92%, 95%, 89%, 78%, 77%, and 77%, respectively. The median disease-specific survival was not reached in all histologic subtypes analyzed; however, there does not appear to be a plateau in disease-specific survival of patients with stage I NHL irrespective of subtypes. Although lymphoma was the most common cause of death (40.7%), death from other cancer (17.4%) and cardiovascular disease (13.6%) were also frequent. Chemotherapy appeared favorably associated with OS in patients with DLBCL, BL, and MCL while patients with FL, MZL, SLL, and PTCL who require chemotherapy for initial treatment showed shorter OS. Patients with stage I NHL have favorable disease-specific survival; however, no plateau was seen regardless of histologic subtypes thus suggesting that patients may need attention and follow-up even in aggressive lymphomas after 5 years of remission.
KW - Disease-specific survival
KW - Radiation
KW - SEER
KW - Stage I lymphoma
UR - http://www.scopus.com/inward/record.url?scp=85059738042&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059738042&partnerID=8YFLogxK
U2 - 10.1007/s00277-018-3571-7
DO - 10.1007/s00277-018-3571-7
M3 - Article
C2 - 30617643
AN - SCOPUS:85059738042
SN - 0939-5555
VL - 98
SP - 1169
EP - 1176
JO - Annals of Hematology
JF - Annals of Hematology
IS - 5
ER -